attyloid GmbH was founded in 2018 and is located in Düsseldorf, Germany.
Building on a strong scientific expertise in protein misfolding and aggregation, we focus our business model on aggregate quantitation for development and QC of biologicals. Our mission is to revolutionize aggregate analytics for safer biologicals at higher yields.
attyloid draws on a strong team of founders with expertise in Life Science, Health Care and Corporate Development.
Dr. Oliver Bannach
Dr. Bannach is a biophysicist by training with a steady focus on applied science. As research scientist at the Forschungszentrum Jülich and the Heinrich Heine University of Düsseldorf, he developed the sFIDA technology for oligomer-based diagnostics of neurodegenerative disorders. Since March 2018 he is CEO and co-founder of attyloid GmbH. To acknowledge his research on Alzheimer’s disease diagnostics as well as his spin-off activities, Dr. Bannach was awarded „Düsseldorf Citizen of the Year 2017“.
Dr. Andreas Kulawik
Dr. Kulawik received his diploma in biology and his PhD from the Heinrich Heine University of Düsseldorf. Since 2018, he is co-founder and COO of attyloid. Dr. Kulawik has deep knowledge and experience in business administration, quality management, and regulatory affairs.
Dr. Christian Zafiu
Christian Zafiu received his PhD in Chemistry from the University of Vienna and has been Post Doc at the University of Natural Resources and Life Science in Vienna and at the Tokyo Institute of Technology. He is working as Post Doc at the Institute of Complex Systems at Research Center Jülich on the sFIDA Technology since 2014 and is Co-founder and CSO of attyloid GmbH. He is an expert in surface chemistry and bioassay development.
Prof. em. Dr. Dr. h.c. Detlev Riesner
Prof. Riesner was chair holder of Biophysics at the Heinrich-Heine-University in Düsseldorf from 1980 to 2007. Further, he was Dean of the Science Faculty and Vice-President of Research. In 2007 he became member of the University’s Board of Trustees. He worked as a research fellow at Princeton University and held a guest professorship at the department of Neurology at the University of California, San Francisco. Prof. Riesner is co-founder of QIAGEN N.V., and was member and chairman of QIAGEN’s Supervisory Board. He was also a member of the supervisory boards of NewLab Bioquality AG, Erkrath, Direvo AG, Köln, and Alantos AG, Heidelberg. Prof. Riesner was a member of the scientific advisory boards of the Friedrich-Löffler-Institute, Isle of Riems, and PrioNet and APRI, both Canada. He received the Max Planck Research Award for international cooperation and the Federal Cross of Merit (Bundesverdienstkreuz 1. Klasse) from the Federal President of Germany.
Prof. Dr. Dieter Willbold
Supervisory Board Chairman
Dieter Willbold is full Professor for “Physical Biology” at the Heinrich Heine University in Düsseldorf and Director at the Institute of Biological Information Processing, Structural Biochemistry (IBI-7) at the Forschungszentrum Jülich. Prof. Willbold is biochemist, biophysicist, structural biologist, and a long-standing expert in the field of Alzheimer’s disease. He has profound expertise in the sFIDA technology platform applied for CNS biomarker development.